| Version 2.5.2.0 |
|
|
Abstract
Grant Number: 1R43AI069577-01 Project Title: Recombinant human defensin for management of ileal Crohn's disease
PI Information: Name Title HUANG, NING nhuang@ventria.com Abstract: DESCRIPTION (provided by applicant): Inflammatory bowel disease (IBD), including Crohn's disease, is a chronic inflammation of the intestine, for which current therapies are inadequate. In industrialized countries, Crohn's disease affects about 1 in 500 individuals, and it is estimated that about 1 million Americans suffer from some form of IBD. Current hypotheses suggest that in the pathogenesis of all forms of IBD, intestinal microbes trigger inflammatory disease in genetically susceptible individuals. Over the past decade, epithelial cells of the intestine, and other tissues, have been identified as a source of defensins and other antimicrobial peptides. These molecules contribute to innate host defense of epithelial surfaces. 1 antimicrobial peptide expressed by epithelial cells of the human small intestine, human defensin-5 (HD5), is the prime focus of experiments in this grant proposal. Recent investigations provide strong evidence that deficient expression of HD5 is a predisposing factor for Crohn's disease of the ileum. Human defensins are currently not available commercially. Our aims seek to use a protein expression system, ExpressTec, which has been developed by Ventria Bioscience, to produce HD5 using cereal grains. Our proposed studies will yield a commercial source of HD5 that could be used to augment the deficient levels of this molecule in the intestine of ileal Crohn's disease patients. Thus, our efforts may result in a novel therapeutic strategy for the treatment of IBD.
Thesaurus Terms:
There are no thesaurus terms on file for this project.
Institution: VENTRIA BIOSCIENCE 4110 N FREEWAY BLVD SACRAMENTO, CA 958341219 Fiscal Year: 2006 Department: Project Start: 01-AUG-2006 Project End: 30-APR-2008 ICD: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES IRG: ZRG1